In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire PLC

Division of Takeda Pharmaceutical Co. Ltd.
www.shire.com

Latest From Shire PLC

How Drug Effects Are Assessed In Renally Impaired Patients Could Be Headed For A Change

US FDA advisory committee finds merit in each of four industry-suggested alternative approaches to the current paradigm for assessing the impact of renal impairment on drug exposures; agency's own 2010 draft guidance does not reflect its current thinking on the design of dedicated pharmacokinetic studies.

 

Advisory Committees Clinical Trials

Reneo Reveals $50m Series A, Mitochondrial Disease Development Plans

The start-up run by ex-Lumena leadership is testing REN001 for rare genetic mitochondrial diseases with two Phase Ib trials under way and plans to start a third later this year.

Financing StartUps and SMEs

Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech

Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.

Deals Business Strategies

More Divestments In Store As Takeda Digests Shire, Faces Expiries

Takeda remains committed to meeting its post-Shire divestment target, as it faces up to $2bn in at-risk revenues from expiries and seeks additional cost synergies. 

M & A Business Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register